Charles River Laboratories International, Inc. (CRL) stock
CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30225% above fair value
$332.16−3.36 (-1.00%)
Close on Nov 17, 2026Market cap $15.86BP/E –Yield –
Charles River Laboratories International total assets
Total assets on the balance sheet at the end of each period.
Charles River Laboratories International's total assets was $7.53B at Jun 27, 2026. For fiscal 2025 it was $7.14B, down 5.2% from the year before. Over ten years it grew 13.2% a year on average. The highest annual figure on record is $8.20B in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $7.14B | -5.2% |
| FY2024 | Dec 28, 2024 | $7.53B | -8.1% |
| FY2023 | Dec 30, 2023 | $8.20B | +7.8% |
| FY2022 | Dec 31, 2022 | $7.60B | +8.2% |
| FY2021 | Dec 25, 2021 | $7.02B | +27.9% |
| FY2020 | Dec 26, 2020 | $5.49B | +17.0% |
| FY2019 | Dec 28, 2019 | $4.69B | +21.7% |
| FY2018 | Dec 29, 2018 | $3.86B | +31.6% |
| FY2017 | Dec 30, 2017 | $2.93B | +8.0% |
| FY2016 | Dec 31, 2016 | $2.71B | +31.1% |
| FY2015 | Dec 26, 2015 | $2.07B | +10.6% |
| FY2014 | Dec 27, 2014 | $1.87B | +14.6% |
| FY2013 | Dec 28, 2013 | $1.63B | +2.9% |
| FY2012 | Dec 29, 2012 | $1.59B | +1.8% |
| FY2011 | Dec 31, 2011 | $1.56B | -10.1% |
| FY2010 | Dec 25, 2010 | $1.73B | -21.4% |
| FY2009 | Dec 26, 2009 | $2.20B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 27, 2026 | $7.53B | -0.4% |
| Q1 FY2026 | Mar 28, 2026 | $7.73B | +2.0% |
| Q4 FY2025 | Dec 27, 2025 | $7.14B | -5.2% |
| Q3 FY2025 | Sep 27, 2025 | $7.51B | -6.1% |
| Q2 FY2025 | Jun 28, 2025 | $7.56B | -4.9% |
| Q1 FY2025 | Mar 29, 2025 | $7.58B | -7.0% |
| Q4 FY2024 | Dec 28, 2024 | $7.53B | -8.1% |
| Q3 FY2024 | Sep 28, 2024 | $8.00B | +5.2% |
| Q2 FY2024 | Jun 29, 2024 | $7.95B | +2.3% |
| Q1 FY2024 | Mar 30, 2024 | $8.15B | +5.9% |
| Q4 FY2023 | Dec 30, 2023 | $8.20B | +7.8% |
| Q3 FY2023 | Sep 30, 2023 | $7.61B | +3.0% |
| Q2 FY2023 | Jul 1, 2023 | $7.77B | +3.2% |
| Q1 FY2023 | Apr 1, 2023 | $7.70B | +8.8% |
| Q4 FY2022 | Dec 31, 2022 | $7.60B | +8.2% |
| Q3 FY2022 | Sep 24, 2022 | $7.38B | +4.6% |
| Q2 FY2022 | Jun 25, 2022 | $7.53B | +12.0% |
| Q1 FY2022 | Mar 26, 2022 | $7.08B | +21.8% |
| Q4 FY2021 | Dec 25, 2021 | $7.02B | +27.9% |
| Q3 FY2021 | Sep 25, 2021 | $7.06B | +35.4% |
| Q2 FY2021 | Jun 26, 2021 | $6.72B | +28.2% |
| Q1 FY2021 | Mar 27, 2021 | $5.81B | +11.7% |
| Q4 FY2020 | Dec 26, 2020 | $5.49B | +17.0% |
| Q3 FY2020 | Sep 26, 2020 | $5.21B | +13.8% |
| Q2 FY2020 | Jun 27, 2020 | $5.24B | +13.3% |
| Q1 FY2020 | Mar 28, 2020 | $5.20B | +32.5% |
| Q4 FY2019 | Dec 28, 2019 | $4.69B | +21.7% |
| Q3 FY2019 | Sep 28, 2019 | $4.58B | +20.7% |
| Q2 FY2019 | Jun 29, 2019 | $4.63B | +19.6% |
| Q1 FY2019 | Mar 30, 2019 | $3.93B | +30.8% |
| Q4 FY2018 | Dec 29, 2018 | $3.86B | +31.6% |
| Q3 FY2018 | Sep 29, 2018 | $3.80B | +32.5% |
| Q2 FY2018 | Jun 30, 2018 | $3.87B | +39.4% |
| Q1 FY2018 | Mar 31, 2018 | $3.00B | +11.3% |
| Q4 FY2017 | Dec 30, 2017 | $2.93B | +8.0% |
| Q3 FY2017 | Sep 30, 2017 | $2.87B | +6.5% |
| Q2 FY2017 | Jul 1, 2017 | $2.77B | – |
| Q1 FY2017 | Apr 1, 2017 | $2.70B | – |
| Q4 FY2016 | Dec 31, 2016 | $2.71B | – |
| Q3 FY2016 | Sep 24, 2016 | $2.69B | – |
See a number that looks wrong?